TRIUMPH-2 obesity without diabetes — my results so far

SarahChen_PharmD said:

The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Adding the numbers, since they settle part of this. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.

Dr.RenalNash said:

I would rather people stopped quoting the 24% as if it were a licensed outcome.

There is a second half to this that has not been said yet. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

Following on from fiona_glasgow — and this may be the naive question:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

Closing the loop on my own question.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.